The US Customs and Border Protection warns drugmakers against misrepresenting product values to evade import rules ahead of ...

President Donald Trump unofficially asked CMS Administrator Mehmet Oz to lead the administration’s talks with drugmakers to ...

Nearly one out of every 20 staff in the FDA offices that oversee drugs and biologics are gone after the Trump administration ...

Plus, news about Sanofi, Servier, BioNova, Arcutis, Roche, Satellos Bioscience, Fore Biotherapeutics, Cinclus Pharma and Zentiva.

Volastra reports promising Phase 1/2 data for VLS-1488 in solid tumors, with good safety and early efficacy signals in ...

Gilead's Trodelvy shows significant improvement in progression-free survival for metastatic triple-negative breast cancer ...

Geoffrey Porges, a longtime biotech analyst and well-known Wall Street figure, stepped down as CFO of the New York biotech ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

Sanofi will acquire Vigil for its oral small molecule TREM2 project, dubbed VG-3927, that is on tap for a Phase 2 in ...

Jazz's Zepzelca + Roche's Tecentriq shows 27% reduced death risk & improved survival in lung cancer trial; FDA application ...

Beam Therapeutics CEO John Evans warns against AI hype in drug development, drawing parallels to past CRISPR expectations, ...

Hinge Health prices IPO at $32/share, valuing company at $3B. CEO Daniel Perez's firm to trade as HNGE on NYSE, raising ...